Patient demographics and disease status
Patient no. . | Age, y . | Sex . | Paraprotein . | Paraprotein level before PBSCT . | Skin involvement . | Extracutaneous manifestations . | Karnofsky performance status before PBSCT, % . |
|---|---|---|---|---|---|---|---|
| 1 | 47 | M | IgG-λ* | 0.1 g/dL | Generalized | GI, CNS, PLM, JC | 30-40 |
| 2 | 55 | F | IgG-λ | 0.1 g/dL | Generalized | None | 80 |
| 3 | 55 | F | IgG-λ | Intermittent positivity never greater than 0.1 g/dL | Acral papules; limited | GI, CT, PN | 70 |
| 4 | 46 | M | IgG-λ | 0.7 g/dL | Generalized | GI | 30-40 |
| 5 | 74 | F | IgG-κ | 0.5 g/dL | Limited | GI | 70 |
| 6 | 58 | M | IgG-λ | 0.3 g/dL | Generalized | GI | 60 |
| 7 | 47 | F | IgG-λ | 0.9 g/dL† | Generalized | PLM, RN | 30 |
| 8 | 43 | F | IgG-λ | 0.5 g/dL | Generalized | CNS, GI, PLM, JC | 50 |
Patient no. . | Age, y . | Sex . | Paraprotein . | Paraprotein level before PBSCT . | Skin involvement . | Extracutaneous manifestations . | Karnofsky performance status before PBSCT, % . |
|---|---|---|---|---|---|---|---|
| 1 | 47 | M | IgG-λ* | 0.1 g/dL | Generalized | GI, CNS, PLM, JC | 30-40 |
| 2 | 55 | F | IgG-λ | 0.1 g/dL | Generalized | None | 80 |
| 3 | 55 | F | IgG-λ | Intermittent positivity never greater than 0.1 g/dL | Acral papules; limited | GI, CT, PN | 70 |
| 4 | 46 | M | IgG-λ | 0.7 g/dL | Generalized | GI | 30-40 |
| 5 | 74 | F | IgG-κ | 0.5 g/dL | Limited | GI | 70 |
| 6 | 58 | M | IgG-λ | 0.3 g/dL | Generalized | GI | 60 |
| 7 | 47 | F | IgG-λ | 0.9 g/dL† | Generalized | PLM, RN | 30 |
| 8 | 43 | F | IgG-λ | 0.5 g/dL | Generalized | CNS, GI, PLM, JC | 50 |
GI indicates gastrointestinal dysmotility; CNS, central nervous system presenting as seizures; PLM, pulmonary dysfunction; JC, joint contractures; CT, carpal tunnel syndrome; PN, peripheral neuropathy; and RN, renal dysfunction.
With bone marrow involvement.
Level at initial evaluation; did not receive PBSCT high-dose treatment.